Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

ImunofanvsThymosin Alpha-1

Synthetic hexapeptide derived from thymopoietin with immunomodulatory, antioxidant, and hepatoprotective properties

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

ImmuneImmune

At a Glance

Quick
comparison

Dose Range

Imunofan

50–100 mcg

Thymosin Alpha-1

1.6–3.2 mg

Frequency

Imunofan

Once daily

Thymosin Alpha-1

Twice weekly

Administration

Imunofan

Subcutaneous injection

Thymosin Alpha-1

Subcutaneous injection

Cycle Length

Imunofan

8-12 weeks

Thymosin Alpha-1

8-12 weeks

Onset Speed

Imunofan

Rapid (hours to days)

Thymosin Alpha-1

Moderate (1-2 weeks)

Evidence Level

Imunofan

Limited human trials

Thymosin Alpha-1

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

Imunofan
Thymosin Alpha-1

Immune

Imunofan90%
Thymosin Alpha-10%

Healing & Recovery

Imunofan70%
Thymosin Alpha-10%

Anti-Aging

Imunofan55%
Thymosin Alpha-10%

Immune Activation

Imunofan0%
Thymosin Alpha-195%

Infection Fighting

Imunofan0%
Thymosin Alpha-192%

Immune Balance

Imunofan0%
Thymosin Alpha-188%

Technical Data

Compound
specifications

Imunofan

Molecular Formula

C36H61N13O10

Molecular Weight

836.0 g/mol

Half-Life

Approximately 2-4 hours (intranasal administration)

Bioavailability

~90-95% (subcutaneous injection)

CAS Number

Not assigned (Russian pharmacopeia compound)

Thymosin Alpha-1

Molecular Formula

C129H215N33O55

Molecular Weight

3108.32 g/mol

Half-Life

Approximately 2 hours

Bioavailability

High when injected subcutaneously (rapid absorption, peak at ~2 hours)

CAS Number

62304-98-7

Protocols

Dosing
tiers

Imunofan

starting

50 mcg subcutaneously or intramuscularly every other day

Every other day

5-15 injections per course (10-30 days)

Standard injection protocol uses 1 mL of 0.005% solution (50 mcg) administered subcutaneously or intramuscularly every other day. A typical course consists of 10-15 injections. For chronic infections and cancer adjuvant therapy, courses may be repeated after a break.

standard

50 mcg per dose, one spray in each nostril once daily

Once daily

10-15 days per course

Intranasal administration provides a non-invasive route with good mucosal absorption. One spray delivers 50 mcg. Convenient for patients who prefer to avoid injections or for maintenance therapy after an initial injection course.

advanced

100 mcg once daily

Once daily

10-20 days per course

Rectal suppositories contain 100 mcg of active ingredient — double the injection dose to compensate for absorption differences. Used when injection and intranasal routes are not suitable, particularly in pediatric populations or patients with needle aversion.

Thymosin Alpha-1

starting

1.6 mg

Twice weekly

4 weeks

This is the standard clinical dose used in most research trials. Start here to assess your tolerance and response. The 1.6 mg dose (sometimes listed as 900 mcg/m2) has decades of safety data behind it.

standard

1.6 mg

Twice weekly

8-12 weeks

The most common protocol used in clinical trials for hepatitis and cancer support. Inject on consistent days (like Monday/Thursday) for best results. This duration allows meaningful immune enhancement.

advanced

1.6 mg daily for 7 days, then twice weekly

Daily initially, then twice weekly

12+ weeks

Used in some severe infection and critical care protocols. The daily loading phase rapidly boots immune function, followed by maintenance. Only under medical supervision for serious conditions.

Applications

Best
suited for

Imunofan

Cancer Adjuvant Therapy

Imunofan enhances the body's reserve capacity to inactivate free radicals and oxidants during chemotherapy and radiation, substantially reducing toxic reactions and enabling continuity of cancer treatment. Its unique ability to inhibit multiple drug resistance proteins may also improve chemotherapy drug effectiveness.

Chronic Viral Hepatitis

With established hepatoprotective properties and immune-restoring capabilities, Imunofan is used as adjunctive therapy in chronic hepatitis B and C, helping restore antiviral immunity and supporting liver function recovery.

Chronic Infections with Immunodepression

Patients with chronic infections (brucellosis, opportunistic infections in HIV) who display cell-mediated immunodepression may benefit from Imunofan's three-phase immune restoration, particularly the sustained slow-phase effect lasting up to 4 months.

Oxidative Stress Reduction

The rapid antioxidant phase makes Imunofan valuable for conditions involving elevated oxidative stress, as it directly inactivates free radicals and peroxide compounds while restoring the body's oxidative-antioxidant balance.

Thymosin Alpha-1

Chronic Hepatitis B or C Support

Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.

Cancer Treatment Support

When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.

Age-Related Immune Decline

As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.

Severe Infection Recovery

In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety Profile

Side
effects

Imunofan

Common

  • Injection site reaction
  • Transient headache
  • Nasal irritation (intranasal form)
  • Transient mild fever
  • Mild fatigue
  • Gastrointestinal discomfort (suppository form)

Uncommon

  • Allergic reaction

Serious

  • Anaphylactic reaction / Severe hypersensitivity

Thymosin Alpha-1

Common

  • Injection site reactions
  • Mild fatigue
  • Flu-like symptoms

Uncommon

  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research Status

Safety
& evidence

Imunofan

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Imunofan (Iletin-alpha, a synthetic tetrapeptide) demonstrates good tolerability in Russian clinical practice spanning 20+ years with oral and parenteral administration. Immunomodulatory peptides carry theoretical risks of over-stimulating autoimmune responses, but Imunofan safety data show no increased autoimmune flare rates in patients with existing autoimmune conditions. Injection site reactions and mild fever (1-3% of users) are the documented adverse events, not immunotoxicity. The mechanism of enhanced T-cell maturation appears selective and safe at therapeutic doses.

Contraindications

  • xKnown hypersensitivity to imunofan or excipients
  • xPregnancy complicated by Rh-conflict (contraindicated)
  • xChildren under 2 years of age
  • xSevere allergic conditions in acute exacerbation

Thymosin Alpha-1

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

FDA approved for other use

Safety Overview

Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • xOrgan transplant recipients on immunosuppressants
  • xActive autoimmune disease flares
  • xKnown allergy to thymosin peptides
  • xPregnancy or breastfeeding
  • xChildren under 18 without medical supervision

Decision Guide

Which is
right for you?

Choose Imunofan if...

  • Immune system restoration and modulation
  • Adjunctive therapy during chemotherapy and radiation
  • Support during chronic hepatitis treatment
  • Reducing oxidative stress and free radical damage

Choose Thymosin Alpha-1 if...

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support